“lenalidomide” Archives

in
Entry Author Date Location
MorphoSys, Incyte Get Early FDA Nod for Antibody Alternative to CAR-T 08/03/20 Europe
Incyte Commits $900M to MorphoSys for Rights to Lymphoma Drug 01/13/20 National
Bio Roundup: Opioids in Court, IPO Parade, Brain Cancer Bet & More 05/31/19 National
Thwarting Opposition, Bristol Gets Shareholder OK for $74B Celgene Buyout 04/12/19 New York
The Life, Troubles, and Celgene Legacy of Deal Guru George Golumbeski 03/11/19 National
Bristol-Myers’ $74B Celgene Buyout Faces Opposition from Wellington 02/27/19 New York
In a Huge Biopharma Shakeup, Bristol-Myers to Buy Celgene For $74B 01/03/19 National
BCMA Day: At ASH ‘18, Cell Therapies For Myeloma Take Center Stage 12/04/18 National
ASH 2018: Three Up, Two Down as Big Blood Disease Meeting Rolls On 12/03/18 National
With New Data, Karyopharm Says It Will Ask for Myeloma Approval 04/30/18 Boston
FDA Refuses to Review Celgene’s MS Drug, Says File “Insufficient” 02/27/18 New York
Immunotherapy Safety Worries Halt Celgene Myeloma Study, Slow 5 Others 09/07/17 New York
Celgene Narrows Its Relationship With Sutro, No Acquisition Coming 08/10/17 New York
Biotech Roundup: Gilead Slump, Celgene Goes Trump, Hemo Data & More 07/29/16 National
ASCO Roundup: Checkpoints, Pushback Against Prices, CAR-T & More 06/02/15 National
East Coast Biotech Roundup: Vertex, Syndax, Build-to-Buy Deals & More 02/20/15 Boston
West Coast Biotech Roundup: NanoString, Sequenom/Agena, CIRM, & More 06/06/14 San Diego
10 Takeaways From New York’s Life Science Disruptors 03/10/14 New York
Celgene Emerges as Biotech’s Shrewdest, Nimblest Dealmaker 08/05/13 National
Celgene Nabs Option to Buy Acetylon for More Than $1.7B 07/29/13 Boston
Celgene Pours $15M Into Acetylon, Takes “Observer” Role on Board 02/09/12 Boston
Page 1 of 1